Table 1 Demographic and clinical characteristics of patients with schizophrenia treated with olanzapine, risperidone or paliperidone
Olanzapine (n = 53) | Risperidone (n = 28) | Paliperidone (n = 30) | p | |
|---|---|---|---|---|
Male, N((%) | 33 (62.3) | 18 (64.3) | 20 (66.7) | 0.92 |
Age, mean ± SD (years) | 35.60 ± 11.26 | 35.04 ± 9.85 | 36.21 ± 11.27 | 0.78 |
Age of onset, mean ± SD(years) | 26.70 ± 8.46 | 24.71 ± 4.81 | 26.17 ± 6.60 | 0.49 |
Duration of illness (years) | 8.96 ± 9.72 | 7.24 ± 6.92 | 10.00 ± 7.54 | 0.72 |
Duration of the prior treatment(years) | 8.12 ± 8.83 | 6.67 ± 7.19 | 9.34 ± 6.79 | 0.69 |
Education (years) | 11.91 ± 3.81 | 12.39 ± 2.46 | 11.03 ± 3.06 | 0.14 |
Alcohol history, N(%) | 9/44 (17.0) | 4/24 (14.3) | 5/25 (16.7) | 0.95 |
Smoking, N(%) | 23/30 (43.4) | 16/12 (57.1) | 15/15 (50.0) | 0.39 |
FGA before screening (FGA/SGA), N(%) | 10/43 (18.9) | 6/22 (21.4) | 7/23 (23.3) | 0.79 |
Family history of schizophrenia, N(%) | 17/36 (32.1) | 7/21 (25.0) | 9/21 (30.0) | 0.70 |